Skip to main content
Medical information Clinical review pending

Genetic Testing

NRAS Mutation Analysis Codons 12 & 13

The NRAS Mutation Analysis Codons 12 & 13 test identifies specific genetic changes in the NRAS gene, which can influence certain cancers. This information helps guide treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Paraffin-embedded tumor tissue block.
Results
Approximately 7-8 days. Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. A doctor's prescription is needed, except in cases of surgery, pregnancy, or travel abroad. Confirm with the laboratory before booking.
Test priceKSh 21,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the NRAS Mutation Analysis Codons 12 & 13 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients diagnosed with melanoma
  • ✓Patients diagnosed with colorectal cancer
  • ✓Individuals with a family history of relevant cancers
  • ✓Patients considering targeted therapy
  • ✓Diagnosis of certain rare cancers
  • ✓Research purposes
02

In plain language

What this test helps you understand

This test helps identify specific mutations in the NRAS gene that can guide cancer treatment decisions, particularly for targeted therapies. It aids in understanding prognosis and potential response to treatment.
The NRAS Mutation Analysis Codons 12 & 13 test is a diagnostic procedure used to detect specific mutations in the NRAS gene. These mutations can be linked to the development and progression of certain types of cancer. Understanding these genetic changes is important for tailoring treatment strategies and predicting how a patient might respond to specific therapies.

This test focuses on codons 12 and 13 within the NRAS gene. Mutations in these specific locations are commonly found in cancers such as melanoma and colorectal cancer, among others. Identifying these mutations allows healthcare providers to make more informed decisions about the best course of treatment for the patient.

This test is typically considered for individuals diagnosed with certain cancers, those with a family history of cancer, or patients preparing for targeted therapy. It provides valuable information for personalized cancer care.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. A doctor's prescription is needed, except in cases of surgery, pregnancy, or travel abroad. Confirm with the laboratory before booking.
SampleParaffin-embedded tumor tissue block.
MethodologySanger Sequencing.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only analyzes codons 12 and 13 of the NRAS gene. It does not detect mutations in other parts of the gene or other cancer-related genes. Results should be interpreted in the context of the patient's overall clinical picture.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The NRAS gene provides instructions for making a protein involved in cell growth and division. Mutations in this gene can contribute to uncontrolled cell growth, leading to cancer.
Codons 12 and 13 are specific locations within the NRAS gene where mutations frequently occur in certain types of cancer. Detecting these mutations can help guide treatment.
A sample of paraffin-embedded tumor tissue is required for this analysis.
A healthcare provider will interpret the results in the context of your medical history and diagnosis. They will discuss the implications for your treatment plan.
Yes, a doctor's prescription is generally required for this test, with exceptions for specific circumstances like surgery, pregnancy, or travel abroad.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp